Company / Revenue
TherapeuticsMD, Inc. Revenue History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.3M
FY2024
5-year range
$1.3M / $70.0M
FY2020-FY2024
Trend
-98.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 10 years, ranging from $1M in FY2024 to $70M in FY2023.
Based on SEC 10-K filings.
$1M in FY2024 with a 5-year CAGR of -40.0%.
Declined from $3M to $1M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -70.3%
- 5-Year CAGR
- -40.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -40.0%, indicating a declining trend.
- In FY2024, revenue decreased 98.1% year-over-year.
- Peak revenue was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.3M | -98.1% |
| FY2023 | $70.0M | +2619.1% |
| FY2022 | $2.6M | -94.8% |
| FY2021 | $49.6M | +208.4% |
| FY2020 | $16.1M | -4.0% |
| FY2019 | $16.8M | -13.3% |
| FY2018 | $19.4M | -3.9% |
| FY2017 | $20.1M | +34.1% |
| FY2016 | $15.0M | +71.2% |
| FY2015 | $8.8M | +129.8% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026